Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M26.3Revenue (TTM) $M0.1Net Margin (%)-10,006.7Altman Z-Score-16.5
Enterprise Value $M19.8EPS (TTM) $-0.6Operating Margin %-12,806.7Piotroski F-Score3
P/E(ttm)--Beneish M-Score-4.0Pre-tax Margin (%)-10,006.7Higher ROA y-yY
Price/Book1.510-y EBITDA Growth Rate %-11.2Quick Ratio2.1Cash flow > EarningsY
Price/Sales2545-y EBITDA Growth Rate %-4.0Current Ratio2.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-42.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-49.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M20.7ROIC % (ttm)-121.4Gross Margin Increase y-yN

Gurus Latest Trades with HEB

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

HEB is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


HEB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STRAYER DAVID RMedical Director 2012-05-18Buy50,000$0.26396.15view
Lander Russel JVP of Process/QualityAssurance 2011-03-01Buy50,000$0.46180.43view
Lander Russel JVP of Process/QualityAssurance 2010-08-23Buy4,910$0.51152.94view
CARTER WILLIAM ACEO, 10% Owner 2010-08-10Sell377,388$0.49163.27view
STRAYER DAVID RMedical Director 2010-06-23Sell50,900$0.55134.55view
STRAYER DAVID RMedical Director 2010-06-16Buy230,586$0.57126.32view
Springate Wayne S.Vice President of Operations 2010-06-15Sell83,104$0.59118.64view
Bernhardt Charles Thomas IIICFO 2010-06-15Sell87,794$0.59118.64view
CARTER WILLIAM ACEO, 10% Owner 2010-06-11Buy500,000$0.6695.45view
Springate Wayne S.Vice President of Operations 2009-12-15Buy877$0.56130.36view

Quarterly/Annual Reports about HEB:

News about HEB:

Articles On GuruFocus.com
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-K/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CEO Sells Highlight: Hemispherx Biopharma Inc, ADESA Inc, Entergy Corp, and Danaher Corp. Aug 15 2010 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Aug 06 2010 
Hemispherx Biopharma Inc (HEB) CEO William A Carter buys 500,000 Shares Jul 01 2010 
Weekly CFO Buys Highlight: Wireless Telecom Group, ValueVision Media, American River Bankshares, Hem Dec 12 2009 
Hemispherx Biopharma Inc (HEB) CFO Charles Thomas Iii Bernhardt buys 2,000 Shares Dec 08 2009 

More From Other Websites
Hemispherx Biopharma Announces Granting of Final Settlement of Derivative and Class Action Case Sep 22 2016
Hemispherx Biopharma Announces Granting of Final Settlement of Derivative and Class Action Case Sep 22 2016
Hemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing Standards Sep 19 2016
Hemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing Standards Sep 19 2016
Philadelphia biotech firm expecting $5M from stock sale Sep 06 2016
Hemispherx Biopharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference Sep 06 2016
Hemispherx Biopharma, Inc. Announces $5 Million Registered Direct Offering Aug 31 2016
Hemispherx Biopharma, Inc. Announces $5 Million Registered Direct Offering Aug 31 2016
Hemispherx Biopharma to Present Data on the Activity of Ampligen® Against Cancer at CHI's 4th... Aug 29 2016
Hemispherx Biopharma to Present Data on the Activity of Ampligen® Against Cancer at CHI’s 4th... Aug 29 2016
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod... Aug 25 2016
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 24 2016
HEMISPHERX BIOPHARMA INC Financials Aug 24 2016
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod... Aug 24 2016
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod... Aug 23 2016
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod... Aug 23 2016
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 19 2016
Hemispherx Biopharma Forms Scientific Advisory Board to Provide Additional Scientific and... Aug 19 2016
Hemispherx Biopharma Forms Scientific Advisory Board to Provide Additional Scientific and... Aug 19 2016
Hemispherx stockholders approve reverse stock split Aug 18 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)